Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 7/20 | 0.60 |
| ▸ | CCNC | P24863 | 2/20 | 0.49 |
| ▸ | CDK8 | P49336 | 2/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.48 |
| ▸ | MAT2A | P31153 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28378770 | 0.98 | FADS1 (0.59) | FADS1CCNCCDK8MCHR1MAT2A | |
| SCHEMBL26393486 | 0.84 | HDAC6 (0.50) | FADS1CCNCCDK8TRPA1GSK3B | |
| SCHEMBL11697624 | 0.82 | FADS1 (0.60) | FADS1MCHR1TRPA1GSK3B | |
| SCHEMBL7214763 | 0.80 | FADS1 (0.56) | FADS1CCNCCDK8GSK3BMAPK1 | |
| SCHEMBL2671952 | 0.79 | PDPK1 (0.58) | FADS1CCNCCDK8GSK3B | |
| SCHEMBL7214758 | 0.79 | GSK3B (0.44) | FADS1CCNCCDK8GSK3BMAPK1 | |
| SCHEMBL26400882 | 0.79 | MAP2K7 (0.50) | FADS1CCNCCDK8GSK3BMAPK1 | |
| SCHEMBL2431672 | 0.79 | FADS1 (0.55) | FADS1GSK3BMAPK1 | |
| SCHEMBL4007120 | 0.79 | GSK3B (0.69) | FADS1CCNCCDK8GSK3BGRM4 | |
| SCHEMBL26394241 | 0.77 | HDAC6 (0.48) | FADS1CCNCCDK8GSK3BGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166117-B | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-113166117-A | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3169325-B1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-107072985-B | Therapeutic inhibiting compounds | 莱福斯希医药公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10266515-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-23 | — | — | US | disclosed |
| US-10259803-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-16 | — | — | US | disclosed |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-09-14 | — | — | US | disclosed |
| EP-3169325-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2017-05-24 | — | — | EP | disclosed |
| US-9611252-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-04-04 | — | — | US | disclosed |
| WO-2017001924-A1 | THERAPEUTIC INHIBITORY COMPOUDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-01-05 | — | — | WO | disclosed |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2016-07-14 | — | — | US | disclosed |
| WO-2016011209-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2016-01-21 | — | — | WO | disclosed |
| WO-2006066899-A1 | NOVEL THROMBIN INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| EP-1674464-A1 | Novel thrombin inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-06-28 | — | — | EP | disclosed |
| EP-1655296-A1 | Thrombin inhibitors | Graffinity Pharmaceuticals AG (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2006045459-A1 | THROMBIN INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | FADS1 1772/4885CCNC 2745/4885CDK8 804/4885 |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | FADS1 1772/4885CCNC 2745/4885CDK8 804/4885 |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | FADS1 1772/4885CCNC 2745/4885CDK8 804/4885 |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | FADS1 1772/4885CCNC 2745/4885CDK8 804/4885 |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | FADS1 1772/4885CCNC 2745/4885CDK8 804/4885 |
| US-10266515-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | FADS1 1772/4885CCNC 2745/4885CDK8 804/4885 |
| US-10259803-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | FADS1 1772/4885CCNC 2745/4885CDK8 804/4885 |
| US-11021463-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | FADS1 1772/4885CCNC 2745/4885CDK8 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.